Clovis Oncology (CLVS) Misses Q4 EPS by 15c

Clovis Oncology (NASDAQ: CLVS) reported Q4 EPS of ($1.88), $0.15 worse than the analyst estimate of ($1.73). Revenue for the quarter came in at $30.4 million versus the consensus estimate of $26.91 million.

For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• Reading (RDI) Tops Q2 EPS by 4c